Skip to main content
AngioLab, Inc. logo

AngioLab, Inc. — Investor Relations & Filings

Ticker · 251280 ISIN · KR7251280004 KO Professional, scientific and technical activities
Open in API
Filings indexed 173 across all filing types
Latest filing 2026-03-26 Board/Management Inform…
Country KR South Korea
Listing KO 251280

About AngioLab, Inc.

https://angiolab.co.kr/

AngioLab, Inc. is a biotechnology company specializing in the discovery and development of angiogenesis inhibitors. The company develops pharmaceuticals and health functional foods to treat diseases associated with the abnormal growth of blood vessels. Its pipeline includes drug candidates targeting conditions such as age-related macular degeneration (AMD), with some candidates having undergone Phase II clinical trials. AngioLab has also developed Ob-X, a functional food ingredient based on its anti-angiogenic research platform.

Recent filings

Filing Released Lang Actions
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 1% confidence The document is a regulatory notice filed with the Financial Services Commission and Korea Exchange regarding the appointment, reappointment, or dismissal of outside directors (사외이사) for 주식회사 안지오랩. It details changes in the board composition and terms of outside directors. This directly corresponds to an announcement of changes in the company’s board of directors, fitting the Board/Management Information category (MANG).
2026-03-26 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled “정기주주총회 결과” (Annual General Meeting Results) and provides the outcome of each resolution (approval of financials, director compensation limits, director reappointments, etc.), including vote counts and percentages. It reports official voting results from the AGM. This matches the “Declaration of Voting Results & Voting Rights Announcements” category.
2026-03-26 Korean
사업보고서 (2025.12)
Annual Report Classification · 1% confidence The document is a 'Business Report' (사업보고서) for the 27th fiscal year (2025) of AngioLab, Inc. It contains comprehensive company information, including corporate history, management changes, capital structure, shareholding details, and articles of incorporation. This document is a formal, mandatory annual filing submitted to the Financial Supervisory Service and the Korea Exchange. It fits the definition of an Annual Report (10-K) as it provides a full yearly overview of company activity and performance. FY 2025
2026-03-18 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a formal notification of the submission of an audit report ('감사보고서 제출') by the company Angiolab. It provides key financial highlights, the auditor's opinion, and the date of receipt, which is characteristic of a regulatory filing announcing the availability of an audit report rather than the full audit report document itself. Following the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement. FY 2025
2026-03-18 Korean
주주총회소집공고
AGM Information Classification · 1% confidence The document is a formal 'Notice of Annual General Meeting' (주주총회소집공고) for AngioLab, Inc. It includes the meeting date, location, agenda items (financial statements, director appointments, remuneration limits), and procedural information for shareholders. While it contains some background information on the industry (Section III), the primary purpose and structure of the document are to formally notify shareholders of the upcoming AGM and provide the necessary materials for voting. This fits the definition of AGM-R (AGM Information/Materials).
2026-03-11 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집 결의) issued by AngioLab. It details the date, location, agenda items (such as financial statement approval, director appointments, and remuneration limits), and provides biographical details for director nominees. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and request their participation/votes. Therefore, it falls under the Proxy Solicitation & Information Statement category.
2026-03-09 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.